CLINICAL_TRIALS
trial_result
· 2014-09-19
Clinical Trial Update: Study of Natalizumab in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Summary
A Phase 1/Phase 2 study evaluating Natalizumab in relapsed/refractory multiple myeloma was terminated, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-09-19